Migrant children face fear and lack safety crossing Mexico, study shows
FILE PHOTO: A child's shoe is seen on the border between Mexico and the United States ahead of the U.S. presidential elections in November, in Ciudad Juarez, Mexico, September 9, 2024. REUTERS/Jose Luis Gonzalez/File Photo
Migrant children crossing Mexico in hopes of reaching the United States face alarming levels of violence, exclusion and prolonged uncertainty before, during and after their journey, according to a study published on Monday by Save the Children and Plan International.
The report, based on 155 interviews conducted between November 2024 and February 2025, found that children fleeing danger at home often do not find the safety and international protection to which they are entitled, but rather new forms of vulnerability that continue to deprive them of their rights.
The interviewees were aged between 7 and 16 years old. They came mostly from Mexico, Honduras and Venezuela, but also from Colombia, Guatemala and more distant locations such as Afghanistan and Haiti.
The number of unaccompanied children traveling through Mexico to reach the United States has more than doubled in recent years, increasing from 69,488 in 2019 to 137,275 in 2023, driven by rising violence, deepening poverty and climate change-related displacement.
"Migrant children are not finding safety when they cross the border into Mexico; they're finding more fear, more waiting, and more lost time," said Reena Ghelani, chief executive of Plan International, a UK-based humanitarian and development organization, in a press release.
"No child should find themselves in this situation, especially after enduring such a perilous journey to find safety. They need support now – including protection, access to safe shelter, education and mental health care. We are seeing families so desperate that children are being forced to consider returning to the very places they fled from. That should never be their only option," she said.
Plan International and Save the Children called for an immediate, coordinated response stating that authorities should strengthen child protection systems in border areas, improve access to education and mental health services, and provide adequate housing that prioritizes children's needs.
The recent deportation of three U.S. citizen children — including one with cancer — to Honduras with their mothers has sparked criticism from human rights advocates. They accuse the administration of U.S. President Donald Trump of deporting children without due process, endangering their lives. REUTERS
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
17 hours ago
- Straits Times
Norwegian gynaecologist jailed for dozens of rapes over 18 years
Norwegian gynaecologist jailed for dozens of rapes over 18 years OSLO – A Norwegian court on June 6 sentenced a doctor to 21 years in prison for committing dozens of rapes over a period of almost two decades. Arne Bye, 55, was found guilty of committing 70 counts of rape and sexual assault during gynecological examinations of his patients between 2004 and 2022. He was also condemned for 80 instances of abuse of his position. Bye committed the acts at his medical practice in the town of Frosta in central Norway. The court in the city of Trondelag barred the doctor from exercising his profession indefinitely and demanded he financially compensate his victims. Ninety-four women testified during the trial, describing how Bye committed multiple acts of non-consensual touching and digital penetration without medical justification. The acts all constitute rape under Norwegian law. Bye also filmed the assaults. 'The suspect's actions make this case an extremely serious one. The actions are unacceptable,' the Adresseavisen newspaper quoted judge Espen Haug as saying in court. The sentence matched the one requested by the prosecution. Bye's defence had argued for lesser sentence, recognising only 20 of the rapes. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
20 hours ago
- Straits Times
South Africa to ramp up vaccinations as foot-and-mouth disease spreads
South Africa is building up vaccine stocks and expanding inoculations to fight a worsening foot-and-mouth disease outbreak, the agriculture ministry said, as the country faces threats to beef supplies. Foot-and-mouth disease is a highly contagious, viral infection of cloven-hoofed animals that may also affect other species. Flare-ups have been reported over the past several months in five of South Africa's nine provinces, with KwaZulu- Natal being the worst affected. This week, Karan Beef, which operates the country's largest feedlot and one of the world's biggest, reported an outbreak at its facility in Heidelberg, about 50 kilometres southeast of Johannesburg. The quarantine imposed on the feedlot, which slaughters about 2,000 cattle daily, could impact beef supplies. The government has ordered over 900,000 doses of foot-and-mouth disease vaccines with the first batch expected to arrive next week, the agriculture ministry said in a statement late on Thursday. "These plans are not only about responding to outbreaks, but also about building permanent infrastructure to manage future risks," it said. There are growing calls by some cattle producers to declare a "state of disaster" and protect the industry from financial losses. Invoking disaster law gives the government additional powers to intervene in a crisis. The foot-and-mouth disease outbreaks have resulted in South African beef and related products being banned in markets such as China, Namibia and Zimbabwe. South Africa's livestock sector is also recovering from its worst avian flu outbreak, which destroyed a third of the national chicken flock in 2023. On Thursday, the government announced the first ever mass vaccination of poultry to prevent a repeat outbreak of high-pathogenic avian influenza (HPAI), a bird flu that spreads rapidly in an infected flock, causing a high death rate. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
a day ago
- Business Times
Lightstone Ventures, Temasek's ClavystBio co-lead Allay Therapeutics' US$57.5 million Series D funding
[SINGAPORE] United States-based biotechnology company Allay Therapeutics on Thursday (Jun 5) announced it has raised US$57.5 million in a Series D financing round, co-led by biotech venture capital (VC) firm Lightstone Ventures and ClavystBio, a Temasek-linked life sciences venture builder. Participants in the round include the following existing investors: New Enterprise Associates, a US-based VC company; healthcare VC firm Arboretum Ventures; Temasek unit Vertex Holdings' growth-stage VC fund Vertex Growth; Vertex's healthcare fund Vertex Ventures Healthcare; and Australian life sciences VC firm Brandon Capital. New investors who joined the round were US VC firm IPD Capital; Singapore government-backed deep tech investor SGInnovate; as well as EDBI, which operates under SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore. Drug manufacturer Maruishi Pharmaceutical has expanded its license agreement with Allay Therapeutics to include South Korea and Taiwan, in addition to Japan. As part of this agreement, Maruishi also participated in the Series D round. Meanwhile, HSBC Innovation Banking, which focuses on banking solutions for start-ups, investors and pre-initial public offering companies, also provided additional venture debt financing to Allay Therapeutics. Founded in 2017, Allay Therapeutics, which was incubated by Lightstone Ventures' Singapore fund and The Foundry, focuses on pain relief. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its technology is used to create analgesic products that can aid patients with post-surgical pain management and recuperation, reducing the need for opoids and improving patient recovery. The company has teams in the US and Singapore. Funds from the Series D round will support the company's registration trial, which started in February this year and involves 200 participants in multiple US sites. The trial evaluates its product for the treatment of pain after total knee replacement surgery. Results from the trial will be available in the third quarter of 2025.
